Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
THCv · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| THCv | DIETARY_SUPPLEMENT | THCv in MCT oil |
THCv is an investigational drug being studied in healthy adults. It is currently in Phase 1 clinical development. THCv has been evaluated in a completed clinical trial to assess its safety, pharmacokinetics, and pharmacodynamics.
THCv is being developed by Canopy Growth Corporation, which trades under the ticker symbol CGC. The company is conducting clinical research on this investigational drug.
THCv is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled study in healthy adults. THCv is still investigational and has not been approved by regulatory authorities.
THCv has been studied in one clinical trial, identified as NCT05210634. This was a Phase 1 study titled 'Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants.' The trial enrolled 21 participants and has been completed.
Yes, THCv is also known as CHI-915. The clinical trial NCT05210634 assessed the safety, pharmacokinetics, and pharmacodynamics of CHI-915 in healthy participants, and this is the same drug referred to as THCv.